The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050

Future Oncol. 2021 Mar;17(7):783-794. doi: 10.2217/fon-2020-0888. Epub 2020 Nov 9.

Abstract

Aim: Patient-reported symptoms, functioning and overall quality of life (QoL) were compared between dacomitinib and gefitinib in ARCHER 1050. Patients & methods: Patients (n = 448) with advanced EGFR mutation-positive non-small-cell lung cancer completed the EORTC-QLQ-C30 questionnaire and its lung-specific module, LC-13. Mean scores over time were analyzed using a mixed model for repeated measures. Results: Both treatments showed early improvement in disease-related symptoms that was maintained during treatment. Treatment-related diarrhea and sore mouth decreased following dose reduction with dacomitinib. There were no clinically meaningful changes in functioning and overall QoL in either treatment group. Conclusion: Longer treatment duration, enabled by dose reduction, allowed patients on dacomitinib to improve treatment-related symptoms and maintain functioning and overall QoL for longer than gefitinib.

Keywords: dacomitinib; health-related quality of life; non-small-cell lung cancer; patient-reported outcomes.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Activities of Daily Living
  • Administration, Oral
  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung / complications
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • ErbB Receptors / genetics
  • Female
  • Gain of Function Mutation
  • Gefitinib / administration & dosage
  • Gefitinib / adverse effects
  • Humans
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Patient Reported Outcome Measures*
  • Progression-Free Survival
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects
  • Quality of Life
  • Quinazolinones / administration & dosage*
  • Quinazolinones / adverse effects
  • Response Evaluation Criteria in Solid Tumors

Substances

  • Protein Kinase Inhibitors
  • Quinazolinones
  • dacomitinib
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib